INS and metabolic dysfunction-associated steatotic liver disease: NAFLD affects the antilipolytic action of insulin and promotes the production of excess free fatty acids (FFAs), increasing the delivery of FFAs to the liver and de novo lipogenesis, and developing secondary insulin resistance [123].